Randomised controlled trials
In 2005, Sir Ian Wilmut said we shouldn't await more evidence before offering stem cell treatments to terminal patients. George Winter challenges attitudes concerning the universal necessity of RCTs
In December 2005, Professor (now Sir) Ian Wilmut, the first director of Edinburgh University's Centre for Regenerative Medicine, called for stem cell treatments to be offered to people with terminal illnesses. He argued that the benefits of offering such treatments before they had been properly evaluated might outweigh the risks, saying, ‘if we wait until things are totally tested and analysed in animals, it will deny some people treatment’ (BBC News, 2005).
This ran counter to the prevailing medical culture of evidence-based medicine (EBM), one definition of which is ‘…the conscientious explicit and judicious use of current best evidence in making decisions about the care of individual patients' (Sackett et al, 1996). EBM has not been universally lauded by the medical profession. For example, the not altogether tongue-in-cheek Clinicians for the Restoration of Autonomous Practice (CRAP) Writing Group (2002) derided the reverence extended towards the randomised controlled trial (RCT) as a pillar of EBM.
Register now to continue reading
Thank you for visiting British Journal of Midwifery and reading some of our peer-reviewed resources for midwives. To read more, please register today. You’ll enjoy the following great benefits:
Limited access to our clinical or professional articles
Unlimited access to the latest news, blogs and video content
Monthly email newsletter